Venom immunotherapy in Europe and the United States
Background Hymenoptera stings are accountable for significant morbidity and deterioration in health-related quality of life due to the allergic reactions they cause, the most severe of which can culminate in fatal anaphylaxis. The availability of high quality venom extracts for use in the diagnosis...
Gespeichert in:
| Veröffentlicht in: | Allergo journal international 2020-03, Vol.29 (2), p.29-37 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 37 |
|---|---|
| container_issue | 2 |
| container_start_page | 29 |
| container_title | Allergo journal international |
| container_volume | 29 |
| creator | Bilò, M. Beatrice Martini, Matteo Corsi, Alice Tontini, Chiara Antonicelli, Leonardo |
| description | Background
Hymenoptera stings are accountable for significant morbidity and deterioration in health-related quality of life due to the allergic reactions they cause, the most severe of which can culminate in fatal anaphylaxis. The availability of high quality venom extracts for use in the diagnosis and treatment of insect venom allergy has improved the prognosis and the health-related quality of life of venom-allergic patients. All over the world subcutaneous venom immunotherapy is currently the most effective form of allergen-based immunotherapy with an early, sustained and long-term efficacy. Even though the type of insect responsible for allergic reactions may be different from Europe and US and therefore also the type of extract, nevertheless indications and contraindications are quite similar, as well as treatment protocols and treatment duration. However, neither the efficacy nor the safety of the treatment are optimal, especially with regard to bee venom immunotherapy, and so there is considerable room for further improvement in these important areas.
Purpose
This review presents the current practice of venom immunotherapy in Europe and United States discussed at the EAACI (European Academy of Allergy and Clinical Immunology) Allergy School on Insect Venom held in Groningen in April 2019. |
| doi_str_mv | 10.1007/s40629-020-00116-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2376271282</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2376271282</sourcerecordid><originalsourceid>FETCH-LOGICAL-c319t-2573a396b442d4bd4bf73a7ff6ee7820322204443a4b5cebdaf6476b85e2343d3</originalsourceid><addsrcrecordid>eNp9kEFLxDAQhYMouKz7BzwFPEcnkzRpj7KsurDgQddrSNtUu9i0Ju1h_73RCnoSBmZ4vPcGPkIuOVxzAH0TJSgsGCAwAM4Vy0_IAnmhGQidn_65z8kqxgMkV8ZBFbgg4sX5vqNt102-H99csMORtp5uptAPjlpf06TSvW9HV9On0Y4uXpCzxr5Ht_rZS7K_2zyvH9ju8X67vt2xSvBiZJhpYUWhSimxlmWaJgm6aZRzOkcQiAhSSmFlmVWurG2jpFZlnjkUUtRiSa7m3iH0H5OLozn0U_DppUGhFWqOOSYXzq4q9DEG15ghtJ0NR8PBfPExMx-T-JhvPiZPITGHYjL7Vxd-q_9JfQLSjWY4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2376271282</pqid></control><display><type>article</type><title>Venom immunotherapy in Europe and the United States</title><source>SpringerLink Journals - AutoHoldings</source><creator>Bilò, M. Beatrice ; Martini, Matteo ; Corsi, Alice ; Tontini, Chiara ; Antonicelli, Leonardo</creator><creatorcontrib>Bilò, M. Beatrice ; Martini, Matteo ; Corsi, Alice ; Tontini, Chiara ; Antonicelli, Leonardo</creatorcontrib><description>Background
Hymenoptera stings are accountable for significant morbidity and deterioration in health-related quality of life due to the allergic reactions they cause, the most severe of which can culminate in fatal anaphylaxis. The availability of high quality venom extracts for use in the diagnosis and treatment of insect venom allergy has improved the prognosis and the health-related quality of life of venom-allergic patients. All over the world subcutaneous venom immunotherapy is currently the most effective form of allergen-based immunotherapy with an early, sustained and long-term efficacy. Even though the type of insect responsible for allergic reactions may be different from Europe and US and therefore also the type of extract, nevertheless indications and contraindications are quite similar, as well as treatment protocols and treatment duration. However, neither the efficacy nor the safety of the treatment are optimal, especially with regard to bee venom immunotherapy, and so there is considerable room for further improvement in these important areas.
Purpose
This review presents the current practice of venom immunotherapy in Europe and United States discussed at the EAACI (European Academy of Allergy and Clinical Immunology) Allergy School on Insect Venom held in Groningen in April 2019.</description><identifier>ISSN: 2197-0378</identifier><identifier>EISSN: 2197-0378</identifier><identifier>DOI: 10.1007/s40629-020-00116-8</identifier><language>eng</language><publisher>Heidelberg: Springer Medizin</publisher><subject>Allergies ; Allergology ; Dermatology ; Environmental Health ; Immunology ; Immunotherapy ; Medicine ; Medicine & Public Health ; Mini-Review ; Quality of life</subject><ispartof>Allergo journal international, 2020-03, Vol.29 (2), p.29-37</ispartof><rights>Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2020</rights><rights>2020© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c319t-2573a396b442d4bd4bf73a7ff6ee7820322204443a4b5cebdaf6476b85e2343d3</citedby><cites>FETCH-LOGICAL-c319t-2573a396b442d4bd4bf73a7ff6ee7820322204443a4b5cebdaf6476b85e2343d3</cites><orcidid>0000-0002-9324-6039</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s40629-020-00116-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s40629-020-00116-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids></links><search><creatorcontrib>Bilò, M. Beatrice</creatorcontrib><creatorcontrib>Martini, Matteo</creatorcontrib><creatorcontrib>Corsi, Alice</creatorcontrib><creatorcontrib>Tontini, Chiara</creatorcontrib><creatorcontrib>Antonicelli, Leonardo</creatorcontrib><title>Venom immunotherapy in Europe and the United States</title><title>Allergo journal international</title><addtitle>Allergo J Int</addtitle><description>Background
Hymenoptera stings are accountable for significant morbidity and deterioration in health-related quality of life due to the allergic reactions they cause, the most severe of which can culminate in fatal anaphylaxis. The availability of high quality venom extracts for use in the diagnosis and treatment of insect venom allergy has improved the prognosis and the health-related quality of life of venom-allergic patients. All over the world subcutaneous venom immunotherapy is currently the most effective form of allergen-based immunotherapy with an early, sustained and long-term efficacy. Even though the type of insect responsible for allergic reactions may be different from Europe and US and therefore also the type of extract, nevertheless indications and contraindications are quite similar, as well as treatment protocols and treatment duration. However, neither the efficacy nor the safety of the treatment are optimal, especially with regard to bee venom immunotherapy, and so there is considerable room for further improvement in these important areas.
Purpose
This review presents the current practice of venom immunotherapy in Europe and United States discussed at the EAACI (European Academy of Allergy and Clinical Immunology) Allergy School on Insect Venom held in Groningen in April 2019.</description><subject>Allergies</subject><subject>Allergology</subject><subject>Dermatology</subject><subject>Environmental Health</subject><subject>Immunology</subject><subject>Immunotherapy</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Mini-Review</subject><subject>Quality of life</subject><issn>2197-0378</issn><issn>2197-0378</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kEFLxDAQhYMouKz7BzwFPEcnkzRpj7KsurDgQddrSNtUu9i0Ju1h_73RCnoSBmZ4vPcGPkIuOVxzAH0TJSgsGCAwAM4Vy0_IAnmhGQidn_65z8kqxgMkV8ZBFbgg4sX5vqNt102-H99csMORtp5uptAPjlpf06TSvW9HV9On0Y4uXpCzxr5Ht_rZS7K_2zyvH9ju8X67vt2xSvBiZJhpYUWhSimxlmWaJgm6aZRzOkcQiAhSSmFlmVWurG2jpFZlnjkUUtRiSa7m3iH0H5OLozn0U_DppUGhFWqOOSYXzq4q9DEG15ghtJ0NR8PBfPExMx-T-JhvPiZPITGHYjL7Vxd-q_9JfQLSjWY4</recordid><startdate>20200301</startdate><enddate>20200301</enddate><creator>Bilò, M. Beatrice</creator><creator>Martini, Matteo</creator><creator>Corsi, Alice</creator><creator>Tontini, Chiara</creator><creator>Antonicelli, Leonardo</creator><general>Springer Medizin</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><orcidid>https://orcid.org/0000-0002-9324-6039</orcidid></search><sort><creationdate>20200301</creationdate><title>Venom immunotherapy in Europe and the United States</title><author>Bilò, M. Beatrice ; Martini, Matteo ; Corsi, Alice ; Tontini, Chiara ; Antonicelli, Leonardo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c319t-2573a396b442d4bd4bf73a7ff6ee7820322204443a4b5cebdaf6476b85e2343d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Allergies</topic><topic>Allergology</topic><topic>Dermatology</topic><topic>Environmental Health</topic><topic>Immunology</topic><topic>Immunotherapy</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Mini-Review</topic><topic>Quality of life</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bilò, M. Beatrice</creatorcontrib><creatorcontrib>Martini, Matteo</creatorcontrib><creatorcontrib>Corsi, Alice</creatorcontrib><creatorcontrib>Tontini, Chiara</creatorcontrib><creatorcontrib>Antonicelli, Leonardo</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Allergo journal international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bilò, M. Beatrice</au><au>Martini, Matteo</au><au>Corsi, Alice</au><au>Tontini, Chiara</au><au>Antonicelli, Leonardo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Venom immunotherapy in Europe and the United States</atitle><jtitle>Allergo journal international</jtitle><stitle>Allergo J Int</stitle><date>2020-03-01</date><risdate>2020</risdate><volume>29</volume><issue>2</issue><spage>29</spage><epage>37</epage><pages>29-37</pages><issn>2197-0378</issn><eissn>2197-0378</eissn><abstract>Background
Hymenoptera stings are accountable for significant morbidity and deterioration in health-related quality of life due to the allergic reactions they cause, the most severe of which can culminate in fatal anaphylaxis. The availability of high quality venom extracts for use in the diagnosis and treatment of insect venom allergy has improved the prognosis and the health-related quality of life of venom-allergic patients. All over the world subcutaneous venom immunotherapy is currently the most effective form of allergen-based immunotherapy with an early, sustained and long-term efficacy. Even though the type of insect responsible for allergic reactions may be different from Europe and US and therefore also the type of extract, nevertheless indications and contraindications are quite similar, as well as treatment protocols and treatment duration. However, neither the efficacy nor the safety of the treatment are optimal, especially with regard to bee venom immunotherapy, and so there is considerable room for further improvement in these important areas.
Purpose
This review presents the current practice of venom immunotherapy in Europe and United States discussed at the EAACI (European Academy of Allergy and Clinical Immunology) Allergy School on Insect Venom held in Groningen in April 2019.</abstract><cop>Heidelberg</cop><pub>Springer Medizin</pub><doi>10.1007/s40629-020-00116-8</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-9324-6039</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2197-0378 |
| ispartof | Allergo journal international, 2020-03, Vol.29 (2), p.29-37 |
| issn | 2197-0378 2197-0378 |
| language | eng |
| recordid | cdi_proquest_journals_2376271282 |
| source | SpringerLink Journals - AutoHoldings |
| subjects | Allergies Allergology Dermatology Environmental Health Immunology Immunotherapy Medicine Medicine & Public Health Mini-Review Quality of life |
| title | Venom immunotherapy in Europe and the United States |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T00%3A46%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Venom%20immunotherapy%20in%20Europe%20and%20the%20United%20States&rft.jtitle=Allergo%20journal%20international&rft.au=Bil%C3%B2,%20M.%20Beatrice&rft.date=2020-03-01&rft.volume=29&rft.issue=2&rft.spage=29&rft.epage=37&rft.pages=29-37&rft.issn=2197-0378&rft.eissn=2197-0378&rft_id=info:doi/10.1007/s40629-020-00116-8&rft_dat=%3Cproquest_cross%3E2376271282%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2376271282&rft_id=info:pmid/&rfr_iscdi=true |